Skip to main content
Log in

Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Based on estrogen receptor (ER) and menopausal status, operable breast cancer (UICC stage I, II, III-a) patients were randomized for adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy, and the effects on the relapse-free survival (RFS) and overall survival (OS) were compared. Tamoxifen (TAM) 20 mg/day was administered orally for 2 years after mastectomy as an adjuvant endocrine therapy in postmenopausal patients. In premenopausal patients, oophorectomy (OVEX) was performed before TAM administration. In the chemotherapy arm (CHEM), patients were given 0.06 mg/kg of body weight of mitomycin C (MMC) intravenously, followed by an oral administration of cyclophosphamide (CPA) 100 mg/day in an administration of a 3-month period and a 3-month intermission. This 6-month schedule was repeated 4 times in 2 years. The chemoendocrine arm (CHEM + TAM) was composed of TAM with MMC + CPA chemotherapy. The patients were randomized according to ER and menopausal status. ER-positive patients were randomized to three arms: OVEX ± TAM, CHEM, and CHEM + TAM. For ER-negative patients there were two arms: CHEM and CHEM + TAM. 1579 patients entered the trial between September 1978 and December 1991, with median follow-up of 8.2 years. In ER-positive, premenopausal patients, there were no significant differences in RFS or OS among OVEX ± TAM, MMC + CPA, TAM + MMC + CPA arms. On the contrary, in ER-positive, postmenopausal patients, the chemoendocrine therapy showed a significantly higher RFS (p = 0.0400) and OS (p=0.0187) as compared with TAM to chemotherapy alone. There were no significant differences in RFS or OS by addition of TAM on the chemotherapy, in both pre- and post-menopausal ER-negative patients. It was concluded that in ER-positive premenopausal breast cancer, endocrine therapy alone may be equivalent in prolonging RFS and OS to chemotherapy or chemoendocrine therapy, and that ER-positive postmenopausal breast cancer may be better controlled with the combination of TAM and chemotherapy, as compared to TAM or chemotherapy alone. The importance of stratification of operable breast cancer by ER and menopausal status, as well as the direct comparisons of different treatments, were stressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1–15, 71–85, 1992

    Google Scholar 

  2. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293–1298, 1993

    Google Scholar 

  3. Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K: A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors. Cancer 61: 2168–2175, 1988

    PubMed  Google Scholar 

  4. Nomura Y, Tashiro H, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 55: 546–551, 1985

    PubMed  Google Scholar 

  5. The Lifetest procedure. SAS/STAT User's Guide, Version 6, Fourth Edition, Volume 2, SAS Institute Inc., Cary, NC: SAS Institute Inc., 1027–1069, 1989

  6. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4594–4601, 1976

    Google Scholar 

  7. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogen. Cancer Res 47: 4355–4360, 1987

    PubMed  Google Scholar 

  8. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433–1439, 1984

    PubMed  Google Scholar 

  9. Sherman BM, Chapler FK, Crickard K, Wycoff D: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64: 398–404, 1979

    PubMed  Google Scholar 

  10. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488–1491, 1991

    PubMed  Google Scholar 

  11. Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9: 1283–1297, 1991

    PubMed  Google Scholar 

  12. Bines J, Oleske DM, Cubleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718–1729, 1996

    PubMed  Google Scholar 

  13. Brincker H, Mouridsen HT, Andersen KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 3: 91–95, 1983

    Article  PubMed  Google Scholar 

  14. Nomura Y, Tashiro H, Hisamatsu K: Drug compliance of adjuvant chemo-, endocrine-, or chemoendocrine treatment for operable breast cancer patients. J Jpn Soc Cancer Therapy 27: 670–677, 1992 (in Japanese with English abstract)

    Google Scholar 

  15. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710–717, 1989

    PubMed  Google Scholar 

  16. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanclli A, Farris A, Castagnetta A, Traina A, Cappellini M, Pacini P, Sassi M, Malacarne P, Donati D, Mustacchi G, Galletto L, Schieppati G, Villa F, Bolognesi A, Gallo L: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. Eur J Cancer 28: 673–680, 1992

    PubMed  Google Scholar 

  17. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459–471, 1986

    PubMed  Google Scholar 

  18. Fisher B, Redmond C, Legault-Poisson S, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Meyers DB, Hochn JL: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of node-positive breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005–1018, 1990

    PubMed  Google Scholar 

  19. Fisher B, Digham J, De Cillis A, Wickerham D, Wolmark N, Emir B, Dimitrov N, Abramson N, Atkins J, Shibata H, Deschenes L: The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node negative patients with estrogen-receptor (ER) positive invasive breast cancer (BC): first results from NSABP B-20. Proc ASCO 16: 1 (abstract), 1997

    Google Scholar 

  20. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider J, O'Sullivan J, Hess E, Martino S: Tamoxifen (T) versus cyclophosphamide, adriamycin and 5FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer; a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc ASCO 16: 450 (abstract), 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nomura, Y., Shirouzu, M. & Takayama, T. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status. Breast Cancer Res Treat 49, 51–60 (1998). https://doi.org/10.1023/A:1005901622642

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005901622642

Navigation